Stem Cell Banking: A Global View

  • Glyn StaceyEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1590)


Stem cell banking has been a topic of discussion and debate for more than a decade since the first public services to supply human embryonic stem cells (hESCs) were established in the USA and the UK. This topic has received a recent revival with numerous ambitious programmes announced to deliver large collections of human induced pluripotency cell (hiPSC) lines. This chapter will provide a brief overview charting the development of stem cell banks, their value, and their likely role in the future.

Key words

Pluripotent stem cell banks Human embryonic stem cells Induced pluripotent stem cells Rationale History Challenges 


  1. 1.
    Rottem S, Naot Y (1998) Subversion and exploitation of host cells by mycoplasma. Trends Microbiol 6:436–440CrossRefPubMedGoogle Scholar
  2. 2.
    MacLeod RAF, Dirks WG, Matsuo Y et al (1998) Widespread intraspecies cross-contamination of human tumour cell lines arising at source. Int J Cancer 83:555–563CrossRefGoogle Scholar
  3. 3.
    Andrews PW, Baker D, Benvinisty N et al (2015) Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI). Regen Med 10(2 Suppl):1–44CrossRefPubMedGoogle Scholar
  4. 4.
    Andrews PW, Arias-Diaz J, Auerbach J et al (2009) Consensus guidance for banking and supply of human embryonic stem cell lines for research purposes. Stem Cell Rev 5(4):301–314CrossRefGoogle Scholar
  5. 5.
    Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282(5391):1145–1147CrossRefPubMedGoogle Scholar
  6. 6.
    Nakagawa M, Koyanagi M, Tanabe K et al (2008) Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 26(1):101–106CrossRefPubMedGoogle Scholar
  7. 7.
    Stacey G, Crook JM, Hei D, Ludwig T (2013) Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells? Cell Stem Cell 13(4):385–388CrossRefPubMedGoogle Scholar
  8. 8.
    Inamdar MS, Healy L, Sinha A, Stacey G (2012) Global solutions to the challenges of setting up and managing a stem cell laboratory. Stem Cell Rev 8(3):830–843CrossRefPubMedGoogle Scholar
  9. 9.
    Stacey G (2012) Banking stem cells for research and clinical applications. Prog Brain Res 200:41–58CrossRefPubMedGoogle Scholar
  10. 10.
    Stacey G, Masters JR (2008) Cryopreservation and banking of mammalian cell lines. Nat Protoc 3(12):1981–1989CrossRefPubMedGoogle Scholar
  11. 11.
    Buta C, David R, Dressel R et al (2013) Reconsidering pluripotency tests: do we still need teratoma assays? Stem Cell Res 11:552–562CrossRefPubMedGoogle Scholar
  12. 12.
    Müller FJ, Goldmann J, Löser P, Loring JF (2010) A call to standardize teratoma assays used to define human pluripotent cell lines. Cell Stem Cell 6(5):412–414CrossRefPubMedGoogle Scholar
  13. 13.
    Müller FJ, Schuldt BM, Williams R et al (2011) A bioinformatic assay for pluripotency in human cells. Nat Methods 8(4):315–317CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Isasi R, Knoppers BM, Andrews PW et al (2012) Disclosure and management of research findings in stem cell research and banking: policy statement. Regen Med 7(3):440–448CrossRefGoogle Scholar
  15. 15.
    Gymrek M, McGuire AL, Golan D et al (2013) Identifying personal genomes by surname inference. Science 339(6117):321–324CrossRefPubMedGoogle Scholar
  16. 16.
    Isasi R (2014) Stem cell research and banking: towards policy on disclosing research results and incidental findings. In: Dusko I (ed) Stem cell banking. Springer, New York, pp 29–40CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  1. 1.UK Stem Cell BankNational Institute for Biological Standards and ControlPotters BarUK

Personalised recommendations